X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (18) 18
humans (16) 16
male (15) 15
female (13) 13
aged (11) 11
middle aged (11) 11
adult (10) 10
hematology, oncology and palliative medicine (8) 8
lung neoplasms - drug therapy (8) 8
lung neoplasms - pathology (8) 8
animals (7) 7
oncology (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
carcinoma, non-small-cell lung - drug therapy (6) 6
chemotherapy (6) 6
lung cancer (6) 6
lung neoplasms - mortality (6) 6
neoplasm staging (6) 6
treatment outcome (6) 6
cancer (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
care and treatment (5) 5
research (5) 5
aged, 80 and over (4) 4
analysis (4) 4
article (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
clinical trials (4) 4
combination (4) 4
disease-free survival (4) 4
dose-response relationship, drug (4) 4
follow-up studies (4) 4
kaplan-meier estimate (4) 4
lung neoplasms - genetics (4) 4
multidisciplinary sciences (4) 4
mutation (4) 4
orthopedics (4) 4
rats (4) 4
biochemistry & molecular biology (3) 3
carcinoma, non-small-cell lung - genetics (3) 3
carcinoma, squamous cell - drug therapy (3) 3
college teachers (3) 3
erlotinib (3) 3
gene (3) 3
growth-factor receptor (3) 3
japan (3) 3
lung cancer, non-small cell (3) 3
medical colleges (3) 3
medicine (3) 3
metaanalysis (3) 3
metastasis (3) 3
mice (3) 3
neurosciences (3) 3
pathogenesis (3) 3
patients (3) 3
pharmaceutical industry (3) 3
plant sciences (3) 3
product development (3) 3
prognosis (3) 3
risk (3) 3
susceptibility (3) 3
therapy (3) 3
young adult (3) 3
1st-line treatment (2) 2
abc transporter (2) 2
abridged index medicus (2) 2
adenocarcinoma (2) 2
adenocarcinoma - drug therapy (2) 2
adenocarcinoma - genetics (2) 2
anatomy (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
apoptosis (2) 2
arabidopsis mutant cev1 (2) 2
atp-binding cassette transporters - antagonists & inhibitors (2) 2
atp-binding cassette transporters - metabolism (2) 2
atpase activity (2) 2
bevacizumab (2) 2
biochemistry (2) 2
biophysics (2) 2
bound atpases (2) 2
brain neoplasms - secondary (2) 2
cancer therapies (2) 2
carbazoles - therapeutic use (2) 2
carboplatin (2) 2
carboplatin-paclitaxel (2) 2
carcinoma, squamous cell - genetics (2) 2
carcinoma, squamous cell - mortality (2) 2
carcinoma, squamous cell - pathology (2) 2
cell biology (2) 2
cell survival - drug effects (2) 2
cells (2) 2
chemistry, multidisciplinary (2) 2
cisplatin - administration & dosage (2) 2
confidence intervals (2) 2
defense responses (2) 2
dental pulp - cytology (2) 2
depsipeptides - pharmacology (2) 2
development and progression (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 141 - 151
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 830 - 838
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | ADENOCARCINOMA | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 663 - 671
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1630 - 1638
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 106 - 113
Journal Article
The Lancet, ISSN 0140-6736, 03/2019, Volume 393, Issue 10176, pp. 1128 - 1137
Journal Article
Journal of Orthopaedics, ISSN 0972-978X, 2018, Volume 15, Issue 3, pp. 878 - 881
AbstractPullout tests to determine the effect of anchor threads on the pullout strength was conducted by using universal testing machine, synthetic cancellous... 
Orthopedics | Suture anchor | Pullout strength | Friction | Anchor threads
Journal Article
Journal of Orthopaedics, ISSN 0972-978X, 2013, Volume 10, Issue 1, pp. 8 - 12
Abstract Purpose Rotator cuff tear is the most common shoulder disease in patients with shoulder problems, but its prevalence is not well known. Methods We... 
Orthopedics | Rotator cuff tear | Asymptomatic | Prevalence | Symptomatic
Journal Article